As already mentioned above, not in serum but in diseased tissue, a distinct reexpression of ED-A+ Fn could be demonstrated in several neoplastic, inflammatory, or cardiovascular disorders qualifying the molecule as an excellent target structure for an antibody based delivery of bioactive payloads or diagnostic agents using the human antibody F8 [15, 32, 63, 64]. Here, FN1 is linked to cardiovascular disorder.